We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+43.82%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$1.32B
AUM Growth
+$367M
Cap. Flow
+$106M
Cap. Flow %
8.07%
Top 10 Hldgs %
60.28%
Holding
65
New
6
Increased
15
Reduced
13
Closed
8

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$74.1M
2
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$64.1M
3
CYTK icon
Cytokinetics
CYTK
+$31.2M
4
PHAT icon
Phathom Pharmaceuticals
PHAT
+$19.8M
5
XOMA
Xoma
XOMA
+$18.9M

Top Sells

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$46.6M
2
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$24.1M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$24.1M
4
MRUS
Merus
MRUS
+$23.6M
5
BPMC
Blueprint Medicines
BPMC
+$19M

Sector Composition

Rank Sector Weight
1 Healthcare 95.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
1
Ionis Pharmaceuticals
IONS
$8.61B
$132M 9.98%
2,179,735
+1,244,187
+133% +$74.1M
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
$119M 8.99%
3,079,155
+235,010
+8% +$5.5M
ACIU icon
3
AC Immune
ACIU
$226M
$96.6M 7.33%
11,342,505
+44,594
+0.4% +$297K
PRNB
4
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$94M 7.13%
+1,716,734
New +$64.1M
CYTK icon
5
Cytokinetics
CYTK
$10.7B
$76.5M 5.8%
7,206,458
+3,040,900
+73% +$31.2M
XOMA
6
DELISTED
Xoma
XOMA
$72.1M 5.47%
2,642,405
+845,463
+47% +$18.9M
ARQL
7
DELISTED
Arqule Inc
ARQL
$59.5M 4.51%
2,978,683
+870,021
+41% +$10.1M
CALA
8
DELISTED
Calithera Biosciences, Inc
CALA
$54.6M 4.14%
477,982
+140,458
+42% +$10.6M
MTEM
9
DELISTED
Molecular Templates, Inc.
MTEM
$47M 3.56%
223,889
-1,485
-0.7% -$213K
MRUS
10
DELISTED
Merus
MRUS
$44.6M 3.38%
3,169,654
-1,469,759
-32% -$23.6M
CBIO
11
Crescent Biopharma
CBIO
$533M
$38.9M 2.95%
73,618
– –
RCUS icon
12
Arcus Biosciences
RCUS
$3.5B
$36.1M 2.74%
3,579,023
– –
FPRX
13
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$35.7M 2.71%
7,783,001
+4,017,833
+107% +$15.9M
REPL icon
14
Replimune Group
REPL
$909M
$33.1M 2.51%
2,309,109
+559,400
+32% +$8.06M
KURA icon
15
Kura Oncology
KURA
$805M
$27.5M 2.08%
1,998,276
– –
XENE icon
16
Xenon Pharmaceuticals
XENE
$6.12B
$25.6M 1.94%
1,949,075
+207,475
+12% +$2.18M
PHAT icon
17
Phathom Pharmaceuticals
PHAT
$759M
$24.5M 1.86%
+785,851
New +$19.8M
PVLA
18
Palvella Therapeutics
PVLA
$2.05B
$19.4M 1.47%
66,874
– –
INFI
19
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$16.7M 1.27%
17,426,968
– –
IMVT icon
20
Immunovant
IMVT
$7.91B
$15.8M 1.2%
+999,996
New +$11.2M
SNDX icon
21
Syndax Pharmaceuticals
SNDX
$1.69B
$15.5M 1.17%
1,764,784
– –
ANAB icon
22
AnaptysBio
ANAB
$1.57B
$15.3M 1.16%
939,565
+585,747
+166% +$13.9M
BPMC
23
DELISTED
Blueprint Medicines
BPMC
$14.7M 1.12%
183,834
-253,731
-58% -$19M
EPIX
24
DELISTED
ESSA Pharma
EPIX
$14.5M 1.1%
2,640,565
– –
LITS
25
Lite Strategy Inc
LITS
$32.8M
$13.3M 1.01%
267,314
+156,250
+141% +$5.81M
1
2 3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2019 Portfolio in Review

As of Q4 2019, BVF Inc held 65 positions worth $1.32B, up 39% from $952M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

BVF Inc deployed $106M of net new capital in Q4 2019, opening 6 new positions and adding to 15 existing holdings. Its largest new stake was Principia Biopharma Inc. Common Stock: 1,716,734 shares worth $94M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier.

On the sell side, the largest reduction was Merus, an estimated $23.6M trimmed.

  • BVF Inc's largest Q4 2019 buy was Principia Biopharma Inc. Common Stock: 1,716,734 shares worth $94M.
  • BVF Inc added most to Ionis Pharmaceuticals in Q4 2019, an estimated $74.1M increase.
  • BVF Inc's biggest Q4 2019 reduction was Merus, cutting an estimated $23.6M.
  • BVF Inc fully exited Lakefront Biotherapeutics American Depositary Shares in Q4 2019, selling an estimated $46.6M.
  • BVF Inc's ten largest holdings make up 60% of its $1.32B portfolio in Q4 2019.
  • BVF Inc opened 6 new positions and closed 8 in Q4 2019.
  • BVF Inc's portfolio value rose 39% quarter-over-quarter to $1.32B.

Based on BVF Inc's 13F filing for Q4 2019, filed 14 Feb 2020.